Adam R.  Craig net worth and biography

Adam Craig Biography and Net Worth

Dr. Adam R. Craig, M.D., Ph.D., is an Executive Vice President - Development, Chief Medical Officer of Sunesis Pharmaceuticals, Inc., since March 1, 2012. From September 2007 until December 2011, Dr. Craig served as Chief Medical Officer of ChemGenex Pharmaceuticals Ltd., a biotechnology company focused on the development of novel therapeutic agents for the treatment of cancer, and in similar roles following the acquisition of ChemGenex by Cephalon, Inc. in July 2011, and the acquisition of Cephalon, Inc. by Teva Pharmaceutical Industries Ltd. in October 2011. From December 2011 until joining the Company, Dr. Craig served as a consultant to Teva Pharmaceutical Industries Ltd. Before joining ChemGenex, he was founding Chief Medical Officer at Innovive Pharmaceuticals, Inc., a hematology-focused company. Prior to joining Innovive, Dr. Craig held positions of increasing responsibility at ArQule Inc., Ilex Oncology Inc., and Antisoma plc. Dr. Craig received his medical qualifications from London University, a Ph.D. in molecular medicine from the University of Leeds, and an M.B.A. from the Open Business School in the United Kingdom. Dr. Craig is a member of the Royal College of Pediatrics and Child Health Physicians (UK) and undertook post-graduate training in pediatrics and pediatric oncology. He also currently serves as a member of the Commercialization Review Council for the Cancer Prevention Research Institute of Texas, a fund for cancer research and prevention programs and services.

What is Adam R. Craig's net worth?

The estimated net worth of Adam R. Craig is at least $267,609.60 as of January 24th, 2023. Dr. Craig owns 29,440 shares of CTI BioPharma stock worth more than $267,610 as of March 28th. This net worth evaluation does not reflect any other investments that Dr. Craig may own. Additionally, Dr. Craig receives an annual salary of $1,090,000.00 as CEO at CTI BioPharma. Learn More about Adam R. Craig's net worth.

How old is Adam R. Craig?

Dr. Craig is currently 57 years old. There are 3 older executives and no younger executives at CTI BioPharma. Learn More on Adam R. Craig's age.

What is Adam R. Craig's salary?

As the CEO of CTI BioPharma Corp., Dr. Craig earns $1,090,000.00 per year. Learn More on Adam R. Craig's salary.

How do I contact Adam R. Craig?

The corporate mailing address for Dr. Craig and other CTI BioPharma executives is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. CTI BioPharma can also be reached via phone at (206) 282-7100 and via email at [email protected]. Learn More on Adam R. Craig's contact information.

Has Adam R. Craig been buying or selling shares of CTI BioPharma?

Adam R. Craig has not been actively trading shares of CTI BioPharma over the course of the past ninety days. Most recently, Adam R. Craig sold 85,317 shares of the business's stock in a transaction on Tuesday, January 24th. The shares were sold at an average price of $6.00, for a transaction totalling $511,902.00. Following the completion of the sale, the chief executive officer now directly owns 29,440 shares of the company's stock, valued at $176,640. Learn More on Adam R. Craig's trading history.

Adam R. Craig Insider Trading History at CTI BioPharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/24/2023Sell85,317$6.00$511,902.0029,440View SEC Filing Icon  
1/3/2023Sell84,683$6.01$508,944.8329,440View SEC Filing Icon  
9/12/2022Sell242,300$6.43$1,557,989.0027,861View SEC Filing Icon  
8/16/2022Buy5,000$5.50$27,500.0027,861View SEC Filing Icon  
7/5/2022Sell27,000$6.00$162,000.0022,861View SEC Filing Icon  
7/1/2022Sell27,000$6.00$162,000.0022,861View SEC Filing Icon  
6/2/2022Sell27,000$6.00$162,000.0016,678View SEC Filing Icon  
12/2/2021Buy3,500$1.52$5,320.00View SEC Filing Icon  
See Full Table

Adam R. Craig Buying and Selling Activity at CTI BioPharma

This chart shows Adam R Craig's buying and selling at CTI BioPharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CTI BioPharma Company Overview

CTI BioPharma logo
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $9.09
Low: $9.09
High: $9.09

50 Day Range

MA: $9.06
Low: $8.91
High: $9.10

2 Week Range

Now: $9.09
Low: $4.01
High: $9.10

Volume

N/A

Average Volume

4,496,004 shs

Market Capitalization

$1.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83